Badanie nad wpływem karbetocyny na zmniejszenie niekontrolowanego głodu u osób z zespołem Pradera-Williego

Prader-Willi syndrome is a rare genetic disorder that causes a range of physical, mental, and behavioral problems. One of the main challenges for people with this condition is hyperphagia, which means an uncontrollable hunger that can lead to overeating. This study is focused on finding out how effective a new treatment, Carbetocin Nasal Spray, is in reducing this excessive hunger in individuals with Prader-Willi syndrome.

The study involves using Carbetocin Nasal Spray, which is a solution administered through the nose. Carbetocin is a chemically synthesized peptide similar to oxytocin, a hormone that plays a role in social bonding and appetite regulation. Participants in the study will receive either the Carbetocin Nasal Spray or a placebo, which looks like the treatment but does not contain the active substance. The purpose of the study is to compare the effects of the Carbetocin Nasal Spray with the placebo to see if it can help manage hyperphagia in people with Prader-Willi syndrome.

Participants will be randomly assigned to one of the two groups and will not know which treatment they are receiving. The study will last for 12 weeks, during which the effects of the treatment on hunger and related behaviors will be monitored. The main goal is to see if there is a significant reduction in the symptoms of hyperphagia, which will be measured using specific questionnaires and assessments. This research aims to provide a better understanding of how Carbetocin Nasal Spray can help manage symptoms in individuals with Prader-Willi syndrome.